ACON  |  Trans Lobby

ACON ("Aids Council of NSW") was a charity set up to advocate for gay men during the AIDS epidemic. Today it's Australia's largest trans lobby group that receives over $15 million in annual government funding and administers the Pride franchise Pride in Sport, Pride in Diversity (workplace), Pride in Health and Well being and the Australian Workplace Equality Index which the Department of Education, Skills and Employment  has signed up for. 

These Pride franchise promote the presumption that gender identity is paramount over sex, and enlist government departments, tertiary institutions and private sector, such as law firms, banks, and corporations, as paying members to ended this position into internal and external policies, marketing and communications, employee behaviours, employ officers to assess and enforce compliance, and collate data on their compliance to be provided to Pride in Diversity. Organisations pay ACON to audit compliance and to be ranked on the Pride in Diversity Australian Workplace Equality Index.

 

The programme imposes a positive and substantial compliance and financial burden on organisations:

 

  • Paying for Pride in Diversity "Diversity and Inclusion" programme training for employees,

  • Imposition of gender theory language such as including pronouns in email signatures and replacing sex-based language with gender-neutral. i.e. replace 'woman' with cervix-havers, menstruate, bodies with vaginas, vulva owners etc.

  • Removal of single sex spaces such as toilets, changing rooms for women and replacing them with 'all gender' or 'gender neutral toilets' allowing males to enter female only spaces.

  • Employing people specifically to ensure compliance with Pride in Diversity's programme in internal and external policies, corporate communications and external marketing;

  • Providing additional special paid leave for employees to undergo sex reassignment or 'gender-affirming' medical procedures and surgeries;

  • Collating and providing data on their compliance to AWEI that Pride in Diversity then uses for own benefit;

  • Expecting employees to perform allegiance to the programme by participating in particular activities;

    • Displaying support and celebrating all the many days, weeks and months of significance in the ACON calendar​

    • Executive sponsorship and fundraising for approved charities and events;

    • Publicly signalling their support with approved corporate branding including purchased merchandise such as lanyards


ACON also hosts the TransHub.org.au website, a repository of gender ideology information mainly aimed at young people distressed about their identity. The ‘gender-affirming’ approach TransHub encourages can include deeply invasive and irreversible medical and surgical interventions. Such interventions are highly controversial, as evidenced recently by major international changes to legal and medical advice.

ACON is also a member of ILGA which receives funding from the ARCUS foundation, a trans funding foundation run by Stryker Medical Corporation a multi-billion pharmaceutical organisation run by Jon Stryker. ILGA World's ECOSOC status with United Nations was removed 10 years ago for it's ties to PIE, Paedophile Information Exchange and NAMBLA, North American Man Boy's Love Association. ILGA denies a paedophile agenda but in March it again pushed for the lowering age of consent for sex with minors. ILGA world is a significant organisation in the trans movement providing change management, sales and marketing to young activists to spread trans activist goals outlined in the Denton's Handbook .

ACON's other ties and sponsors in the pharmaceutical industry from the Pride in Inclusion member list are:

  • AstraZeneca Pty Ltd

  • Eli Lilly

  • Johnson & Johnson Family of Companies, Australia

  • Novartis

  • Pfizer

  • Roche Products Pty Ltd

  • Sanofi Aventis Australia


Transhub.org in effect acts as a marketing arm of the Pharmaceutical and Medical industry in promoting gender transitioning for youth, products and services despite the risk to the physical and mental well-being of youth. 

TransHub downplays not only the risks of these interventions, but also the proven ‘watch and wait’ alternatives to immediate transition, especially for vulnerable children.   (‘Watch and wait’ approach is a traditional form of ‘talk therapy’ that reconciles youth with their sex. The outcome for this solution according to transgendertrend.com’s analysis of over 10 studies shows that the majority of children treated for gender dysphoria, between 73 and 88 percent were observed to cease a transgender identity and reconcile with their biological sex.
In other words, they grew out of gender dysphoria. 

 

From a Pharmaceutical’s business point of view a ‘watchful waiting’ approach only benefits a small number of trained psychologists and there is no recurrent or residual revenue when cured patients exit the market. However if youth are encouraged to take a transition pathway (gender affirmation model) they are worth approximately 150K  per person over their lifetime in order to create and maintain the appearance of the opposite sex.  Not just from initial surgeries but from medical products and procedures that provide the pharmaceutical industry an annual recurring revenue stream.)

ACON’s push for youth to medically transform their bodies, means that, that 73-98% that normally would exit the system will follow instead a path that results in irreversible damage to healthy bodies and become lifelong patients.